Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis
This study suggests that the use of GLP-1RAs can improve RA disease activity and cardiovascular risk profile. Although further research is needed, this novel finding has significant clinical implications because it suggests that anti-obesity medications may improve both cardiovascular and RA outcomes.
Authors
- Thomas H. Welsh (ORCID: https://orcid.org/0000-0003-2212-172X)
- David A. Kellner (ORCID: https://orcid.org/0000-0001-6510-364X)
- Elizabeth Dente (ORCID: https://orcid.org/0000-0002-7127-6130)
- Joshua F. Baker (ORCID: https://orcid.org/0000-0003-0799-7563)
- Vincent Tran (ORCID: https://orcid.org/0000-0002-5659-3859)
- David A. Elashoff (ORCID: https://orcid.org/0000-0002-5865-8580)
- Veena K. Ranganath
- Angshuman Saha
- Victor Tran
Institutions
- University of California, Los Angeles (US)
- Philadelphia VA Medical Center (US)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/acr2.70103
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- National Institutes of Health
- University of California, Los Angeles